Is CITIUS ONCOLOGY, INC. (CTOR) Halal?
Shariah Screening — 5 Standards
Based on financial data from September 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 4.2% / 30% | 4.4% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 4.2% / 33% | 4.4% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 3.8% / 33% | 3.9% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| S&P | 4.2% / 33% | 4.4% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 3.8% / 33% | 3.9% / 33% | 0.0% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 80.0% | |
| Operating Margin | -133.2% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -47.4% | |
| Return on Assets (ROA) | -14.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$5M |
| Free Cash Flow | -$11M |
| Total Debt | $4M |
| Debt-to-Equity | 6.5 |
| Current Ratio | 0.8 |
| Total Assets | $101M |
Price & Trading
| Last Close | $0.54 |
| 50-Day MA | $1.00 |
| 200-Day MA | $1.61 |
| Avg Volume | 299K |
| Beta | 3.0 |
|
52-Week Range
$0.51
| |
About CITIUS ONCOLOGY, INC. (CTOR)
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is CITIUS ONCOLOGY, INC. (CTOR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), CITIUS ONCOLOGY, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is CITIUS ONCOLOGY, INC.'s debt ratio?
CITIUS ONCOLOGY, INC.'s debt ratio is 4.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.8%.
What are CITIUS ONCOLOGY, INC.'s key financial metrics?
CITIUS ONCOLOGY, INC. has a market capitalization of $45M. Return on equity stands at -47.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.